Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3110-3120

  Gautam, Nagsen ^a   Roy, Upal ^b   Balkundi, Shantanu ^b   Puligujja, Pavan ^b   Guo, Dongwei ^a   Smith, Nathan ^b   Liu, Xin Ming ^b   Lamberty, Benjamin ^b   Morsey, Brenda ^b   Fox, Howard S ^b   McMillan, JoEllyn ^b   Gendelman, Howard E ^b   Alnouti, Yazen ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; LOPINAVIR; RITONAVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; HAPLORHINI; LUNG; MACROPHAGE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SKIN; SPLEEN; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; MACACA MULATTA; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; TISSUE DISTRIBUTION;

EID: 84879014036     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00267-13     Document Type: Article

References (43)

1. Ellis R, Langford D, Masliah E. 2007. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat. Rev. Neurosci. 8:33-44. (Pubitemid 46011997)
2. Work Group for HIV and Aging Consensus Project. 2012. Summary report from the Human Immunodeficiency Virus and Aging Consensus Project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J. Am. Geriatr. Soc. 60:974-979.
3. Pasternak AO, de Bruin M, Jurriaans S, Bakker M, Berkhout B, Prins JM, Lukashov VV. 2012. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J. Infect. Dis. 206:1443-1452.
4. Coiras M, Lopez-Huertas MR, Alcami J. 2010. HIV-1 latency and eradication of long-term viral reservoirs. Discov. Med. 9:185-191.
5. Rao KS, Ghorpade A, Labhasetwar V. 2009. Targeting anti-HIV drugs to the CNS. Expert Opin. Drug Deliv. 6:771-784.
6. Anabwani G, Navario P. 2005. Nutrition and HIV/AIDS in sub-Saharan Africa: an overview. Nutrition 21:96-99. (Pubitemid 40136564)
7. Piot P, Bartos M, Ghys PD, Walker N, Schwartlander B. 2001. The global impact of HIV/AIDS. Nature 410:968-973. (Pubitemid 32335847)
8. Thaker HK, Snow MH. 2003. HIV viral suppression in the era of antiretroviral therapy. Postgrad. Med. J. 79:36-42. (Pubitemid 36237877)
9. Rathbun RC, Lockhart SM, Stephens JR. 2006. Current HIV treatment guidelines-an overview. Curr. Pharm. Des. 12:1045-1063.
10. Crowe S, Zhu T, Muller WA. 2003. The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J. Leukoc. Biol. 74:635-641. (Pubitemid 38040338)
11. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. 2002. Patient adherence to HIV medication regimens: a review of published and abstr reports. Patient Educ. Couns. 46:93-108. (Pubitemid 34175086)
12. Rathbun RC, Farmer KC, Stephens JR, Lockhart SM. 2005. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study. Clin. Ther. 27:199-209. (Pubitemid 40462013)
13. Roy U, McMillan J, Alnouti Y, Gautum N, Smith N, Balkundi S, Dash P, Gorantla S, Martinez-Skinner A, Meza J, Kanmogne G, Swindells S, Cohen SM, Mosley RL, Poluektova L, Gendelman HE. 2012. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocytereconstituted mice. J. Infect. Dis. 206:1577-1588.
14. Dash PK, Gendelman HE, Roy U, Balkundi S, Alnouti Y, Mosley RL, Gelbard HA, McMillan J, Gorantla S, Poluektova LY. 2012. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS 26: 2135-2144.
15. Swindells S, Flexner C, Fletcher CV, Jacobson JM. 2011. The critical need for alternative antiretroviral formulations, and obstacles to their development. J. Infect. Dis. 204:669-674.
16. Novitsky V, Essex M. 2012. Using HIV viral load to guide treatment-forprevention interventions. Curr. Opin. HIV AIDS 7:117-124.
17. Sterling TR, Pham PA, Chaisson RE. 2010. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin. Infect. Dis. 50(Suppl 3):S223-S230.
18. Nowacek AS, Miller RL, McMillan J, Kanmogne G, Kanmogne M, Mosley RL, Ma Z, Graham S, Chaubal M, Werling J, Rabinow B, Dou H, Gendelman HE. 2009. Nano ART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) 4:903-917.
19. Nowacek A, Gendelman HE. 2009. Nano ART, neuro AIDS and CNS drug delivery. Nanomedicine (Lond) 4:557-574.
20. Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, Kipp J, Rabinow B, Gendelman HE. 2009. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuro AIDS. J. Immunol. 183:661-669.
21. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. 2006. Development of a macrophagebased nanoparticle platform for antiretroviral drug delivery. Blood 108: 2827-2835.
22. Nowacek AS, Balkundi S, McMillan J, Roy U, Martinez-Skinner A, Mosley RL, Kanmogne G, Kabanov AV, Bronich T, Gendelman HE. 2011. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J. Control Release 150:204-211.
23. Kadiu I, Nowacek A, McMillan J, Gendelman HE. 2011. Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond) 6:975-994.
24. Nowacek AS, McMillan J, Miller R, Anderson A, Rabinow B, Gendelman HE. 2010. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuro AIDS therapeutics. J. Neuroimmune Pharmacol. 5:592-601.
25. Kanmogne GD, Singh S, Roy U, Liu X, McMillan J, Gorantla S, Balkundi S, Smith N, Alnouti Y, Gautam N, Zhou Y, Poluektova L, Kabanov A, Bronich T, Gendelman HE. 2012. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int. J. Nanomedicine 7:2373-2388.
26. Kabanov AV, Gendelman HE. 2007. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog. Polym. Sci. 32:1054-1082. (Pubitemid 47198293)
27. Gendelman HE, Kabanov A, Linder J. 2008. The promise and perils of CNS drug delivery: a video debate. J. Neuroimmune Pharmacol. 3:58. doi: 10.1007/s11481-008-9103-9.
28. Balkundi S, Nowacek AS, Veerubhotla RS, Chen H, Martinez-Skinner A, Roy U, Mosley RL, Kanmogne G, Liu X, Kabanov AV, Bronich T, McMillan J, Gendelman HE. 2011. Comparative manufacture and cellbased delivery of antiretroviral nanoformulations. Int. J. Nanomedicine 6:3393-3404.
29. Balkundi S, Nowacek AS, Roy U, Martinez-Skinner A, McMillan J, Gendelman HE. 2010. Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. J. Vis. Exp. 2010: e2460. doi:10.3791/2460.
30. Huang J, Gautam N, Bathena SP, Roy U, McMillan J, Gendelman HE, Alnouti Y. 2011. UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879:2332-2338.
31. Casey CA, Kragskow SL, Sorrell MF, Tuma DJ. 1987. Chronic ethanol administration impairs the binding and endocytosis of asialoorosomucoid in isolated hepatocytes. J. Biol. Chem. 262:2704-2710.
32. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. 2007. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 13:1324-1332. (Pubitemid 350073596)
33. Liu W, Hou Y, Chen H, Wei H, Lin W, Li J, Zhang M, He F, Jiang Y. 2011. Sample preparation method for isolation of single-cell types from mouse liver for proteomic studies. Proteomics 11:3556-3564.
34. Foisy MM, Yakiwchuk EM, Hughes CA. 2008. Induction effects of ritonavir: implications for drug interactions. Ann. Pharmacother. 42: 1048-1059.
35. Havlir DV, O'Marro SD. 2004. Atazanavir: new option for treatment of HIV infection. Clin. Infect. Dis. 38:1599-1604. (Pubitemid 38738558)
36. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. 1998. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci. 87:1305-1307. (Pubitemid 28514132)
37. Bansal T, Akhtar N, Jaggi M, Khar RK, Talegaonkar S. 2009. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov. Today 14:1067-1074.
38. Schmidt S, Gonzalez D, Derendorf H. 2010. Significance of protein binding in pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 99: 1107-1122.
39. Barrail-Tran A, Mentre F, Cosson C, Piketty C, Chazallon C, Gerard L, Girard PM, Taburet AM. 2010. Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV infected patients included in the ANRS 107 trial. Antimicrob. Agents Chemother. 54:614-619.
40. Cohen J. 2011. HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts. Science 334:1614. doi:10.1126/science.334.6063.1614.
41. Robinson BS, Riccardi KA, Gong YF, Guo Q, Stock DA, Blair WS, Terry BJ, Deminie CA, Djang F, Colonno RJ, Lin PF. 2000. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44:2093-2099. (Pubitemid 30484432)
42. Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, Green BE, Fino L, Park CH, Kong XP, Wideburg NE, Saldivar A, Ruiz L, Kati WM, Sham HL, Robins T, Stewart KD, Hsu A, Plattner JJ, Leonard JM, Norbeck DW. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. U. S. A. 92:2484-2488.
43. Arnaout MA. 1990. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 75:1037-1050. (Pubitemid 20086807)